Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) continues to make strides in the fight against antibiotic-resistant bacterial infections with its experimental compound RECCE® 327 Gel (R327G), this time dosing patients suffering Gram-positive and Gram-negative bacterial infections.
Administered through the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS) Category A by qualified medical professionals, five patients treated with R327G responded well with complete eradication of their infections.
Clinical trial preparations are underway for the use of R327G as a topical application.
Case studies
In "Patient Case Study Example C," a 51-year-old female with a slow-healing wound after ankle infusion surgery was unresponsive to Augmentin (Amoxicillin) and Keflex (Cefalexin), two widely used antibiotics for bacterial infections.
Following seven days of R327G treatment, the wound's redness and swelling subsided and subsequently, healed and closed within 21 days.
"Patient Case Study Example D" was a 51-year-old male who faced recurrent infection after an above-the-knee amputation and osseointegration procedure following a motor bike accident in 2017.
R327G applied over 14 days resulted in wound improvement, with no further signs of redness or swelling.
"Patient Case Study Example E" revolved around an 84-year-old male with osteomyelitis in his left big toe who was not responding to antibiotics.
The infection cleared within seven days of treatment with R327G and eliminated the need for surgical intervention that was otherwise considered inevitable.
Promising alternative
These case studies underscore R327G's potential to offer effective alternatives for patients who are unresponsive to traditional antibiotics.
However, it is important to note that while these case studies provide promising insights, they have not been approved for use in humans and are not part of formal clinical trials.
That said, Recce will continue to research and test the safety and efficacy of R327G in the treatment of antibiotic-resistant bacterial infections.
“We are thrilled to see R327G having a real-life impact with patients, especially those not responding to commonly used antibiotics thanks to the TGA’s special access scheme,” Recce chief executive officer James Graham said.
“We look forward to building upon these successes among the present and future clinical trials ahead.”